Full List/Placing& Open Offer

Oxford Biomedica PLC
12 March 2001

                              
 Not for release, publication or distribution in or into the
              United States, Canada, Australia,
              Japan or the Republic of Ireland
                              
                    OXFORD BIOMEDICA PLC
                              
               Admission to the Official List
                              
 Placing of 54,550,000 new Ordinary Shares at 55p per share
             to raise approximately £30 million
                              
  Open Offer of up to 19,149,701 new Ordinary Shares at 55p
                          per share

The  Board of Oxford BioMedica announced today that  it  has
applied  to  the  UK  Listing Authority  for  the  Company's
172,347,312  Existing Ordinary Shares, and up to  73,699,701
New Ordinary Shares issued pursuant to a Placing and an Open
Offer,  to  be  admitted to the Official List and  for  such
shares  to  be  admitted  to trading  on  the  London  Stock
Exchange.   The  Company has been listed on the  Alternative
Investment Market since December 1996.

The  Company is proposing to raise approximately £27 million
net  of  expenses by means of a firm Placing which has  been
fully  underwritten by Rothschild and Beeson Gregory jointly
and  up  to approximately £10 million through an Open Offer.
The Open Offer is not being underwritten.

The  proceeds of the Placing and the Open Offer will be used
to  continue  to strengthen the Company and to progress  the
candidate  products  to  a  stage where  they  can  generate
significant revenues for the Group.

Summary

*     Admission to the Official List and to trading  on  the
      London Stock Exchange.
*     Placing  to  raise approximately £27 million  (net  of
      expenses)  and up to approximately £10 million through  
      an Open Offer.
*     The  Placing has been fully underwritten by Rothschild
      and Beeson Gregory jointly.
*     The  Directors intend to use the proceeds to  increase
      the  clinical   trial   programme,  continue to  build 
      alliances with major pharmaceutical companies, further
      strengthen  its  intellectual  property  position  and 
      establish a US operation.
*     Admission is expected to become effective and  dealing
      in  the  Existing  Ordinary  Shares  and  New Ordinary 
      Shares to commence on Tuesday, 17 April 2001.

Commenting,  Alan  Kingsman,  Chief  Executive   of   Oxford
BioMedica, said:

'Oxford  BioMedica's move to the Official List  has  been  a
long  held  ambition  for  us and we  are  pleased  to  have
achieved  this  goal.   Simultaneously,  we  have  raised  a
substantial  sum  for the development of  the  Company  with
respect  to its product pipeline, intellectual property  and
international  presence.  It has been important  to  achieve
these goals now in order to take advantage of new commercial
and  corporate opportunities.  We have been fully  supported
in  this  by a range of quality UK and European institutions
during a particularly difficult time for the biotech sector.
We  believe  that  this is a very positive endorsement  from
investors, reflecting Oxford BioMedica's growing standing in
the biotech sector and its long term potential.'
                              
Timetable

Record date for the Open Offer             Friday, 2 March 2001

Latest time and date for splitting       3.00 p.m., Thursday, 5
Application Forms                                    April 2001
(to satisfy bona fide market claims)

Latest time and date for receipt of        3.00 p.m., Monday, 9
completed Application Forms and                      April 2001
payment in full under the Open Offer

Latest time and date for receipt of      4.00 p.m., Tuesday, 10
forms of proxy                                       April 2001

Time and date of Extraordinary General  4.00 p.m., Thursday, 12
Meeting                                              April 2001

Admission and commencement of dealings   Tuesday, 17 April 2001
in the Existing Ordinary Shares and 
New Ordinary Shares

CREST accounts credited                 Thursday, 19 April 2001
                                                               
Despatch of share certificates          Thursday, 26 April 2001


For further information:

Oxford BioMedica plc                         [phone]
Alan Kingsman, Chief Executive

N M Rothschild & Sons Limited               [phone]
Tony Stuart

Beeson Gregory Limited                      [phone]
Nick Rodgers

Merlin Financial                            [phone]
David Simonson
Melanie Toyne Sewell

HCC De Facto Group                          [phone]
Chris Gardner




Rothschild, which is regulated by The Securities and Futures
Authority  Limited,  is  acting  as  financial  adviser  and
sponsor  to  Oxford  BioMedica plc in  connection  with  the
Admission,  the Placing and the Open Offer and no  one  else
and  will not be responsible to any person other than Oxford
BioMedica plc, for providing the protections afforded to its
customers  or  for  providing  advice  in  relation  to  the
Admission, the Placing and the Open Offer.

Beeson  Gregory,  which is regulated by the  Securities  and
Futures  Authority Limited, is acting as  broker  to  Oxford
BioMedica plc in connection with the Admission, the  Placing
and  the  Open  Offer  and  no one  else  and  will  not  be
responsible  to any person other than Oxford BioMedica  plc,
as  broker,  for providing the protections afforded  to  its
customers  or  for  providing  advice  in  relation  to  the
Admission, the Placing and the Open Offer.

The Open Offer is not being made, directly or indirectly, in
or  into,  or  by  use  of the mails, or  by  any  means  or
instrumentality  (including, without  limitation,  facsimile
transmission, telex or telephone) of interstate  or  foreign
commerce,   or  any  facilities  of  a  national  securities
exchange  of  the  United States or  Canada  and  cannot  be
accepted by any such use, means, instrumentality or facility
in  or  from within the United States or Canada and  is  not
being made directly or indirectly in or into the Republic of
Ireland, Australia or Japan.

This document is not an offer of securities for sale in  the
United States and the New Ordinary Shares have not been, and
will  not  be, registered under the United States Securities
Act of 1933 (as amended), nor under the laws of any state of
the  United States, and the relevant clearances have not and
will  not  be  obtained  from the  relevant  authorities  in
Canada,  the  Republic  of  Ireland,  Australia  or   Japan.
Accordingly, New Ordinary Shares may not be offered, sold or
delivered   directly,  or  indirectly  in   or   into   such
jurisdictions.

This  document  contains a summary of information  extracted
from the Prospectus dated 12 March 2001, copies of which are
available for inspection at the Document Viewing Facility of
the  Financial  Services Authority, 25 The North  Colonnade,
London  E14 5HS during normal business hours on any  weekday
(excluding  Saturday, Sunday and public holidays)  from  the
date  of  this  announcement up to and including  Monday,  9
April 2001.


                              
 Not for release, publication or distribution in or into the
              United States, Canada, Australia,
              Japan or the Republic of Ireland
                              
                    OXFORD BIOMEDICA PLC
                              
               Admission to the Official List
                              
 Placing of 54,550,000 new Ordinary Shares at 55p per share
             to raise approximately £30 million
                              
  Open Offer of up to 19,149,701 new Ordinary Shares at 55p
                          per share

Introduction

The  Board of Oxford BioMedica announced today that  it  has
applied  to  the  UK  Listing Authority  for  the  Company's
172,347,312  Existing Ordinary Shares, and up to  73,699,701
New Ordinary Shares issued pursuant to a Placing and an Open
Offer,  to  be  admitted to the Official List and  for  such
shares  to  be  admitted  to trading  on  the  London  Stock
Exchange.   The  Company has been listed on the  Alternative
Investment Market since December 1996.

The  Company is proposing to raise approximately £27 million
net  of  expenses by means of a firm Placing which has  been
fully  underwritten by Rothschild and Beeson Gregory jointly
and  up  to approximately £10 million through an Open Offer.
The Open Offer is not being underwritten.

Information on Oxford BioMedica

Oxford   BioMedica  specialises  in  the   development   and
application  of gene-based therapeutics using advanced  gene
delivery technologies.  The Company has a broad portfolio of
technologies   including  genes,  tumour   antigens,   viral
vectors,  targeted  gene delivery and antibodies  which  are
protected  by  54 patent families, including  9  in-licensed
patent families.  Oxford BioMedica has a pipeline of product
candidates  in  research and development  of  which  a  gene
therapy   product,  MetXia,  for  cancer  and  a  gene-based
immunotherapy product, TroVax, for cancer are in Phase  I/II
clinical trials.

Oxford  BioMedica  has  a strategy to  pursue  the  in-house
development  of  key  products in the areas  of  cancer  and
neurodegenerative disease, while simultaneously placing  the
same  technology and product components alongside  those  of
collaborative  partners,  who generally  fund  the  research
programme,  to  generate  new  product  opportunities.   The
formation of the Gene Discovery Division in August 2000  has
further  enabled Oxford BioMedica to diversify  its  revenue
generation  strategy by utilising its proprietary technology
to    provide   target   validation   systems   and   target
identification to the pharmaceutical industry.

During  the  past  year, Oxford BioMedica  has  divided  its
operations  into  three divisions: Gene Therapy,  Gene-based
Immunotherapy and Gene Discovery.
  
Gene Therapy Division

Oxford  BioMedica has development programmes  and  candidate
products  in  the therapeutic areas of cancer, neurobiology,
cardiovascular disease and HIV infection.  The most advanced
product  currently  in  development  is  MetXia   which   is
currently  in  Phase  I/II clinical trials  for  breast  and
ovarian  cancer.  These trials are currently anticipated  to
be completed in Q4 2001.  Oxford BioMedica also has a number
of products in preclinical development, being  MetXia-VM (in
collaboration  with  PolyMASC for  cancer),   MetXia-MG  (in
collaboration  with IDM for cancer), ProSavin   (Parkinson's
disease),   ImmStat (AIDS/HIV) and an angiogenesis programme
(in collaboration with Aventis for cardiovascular disease).

Gene-based Immunotherapy Division

Oxford  BioMedica's  current  immunotherapy  programmes  are
directed  towards  cancer with TroVax as its  lead  product.
TroVax  is  currently  in  Phase I/II  clinical  trials  for
colorectal cancer, which are anticipated to complete  in  Q2
2002.   TroVax-VET  is also in preclinical  development  for
veterinary cancer in collaboration with Virbac, and under  a
collaboration  agreement with IDM  Oxford  BioMedica  is  in
preclinical development of two further candidate products in
cancer  (TroVax-DC and BetOvac-MG).   Oxford BioMedica  also
has  a  number  of  additional  projects  currently  in  the
research  phase  including  collaborations  with  Wyeth  and
Nycomed Amersham.

Gene Discovery Division

The  gene  discovery  programme utilises Oxford  BioMedica's
proprietary   gene  transfer  technology  to   provide   the
pharmaceutical industry with what the Directors  believe  to
be a novel gene hunting approach. Oxford BioMedica is active
in  two  main  areas  of gene discovery:  Target  Validation
(utilising the Company's LentiVector  technology) and Target
Identification    (utilising   the   Company's    Smartomics
technology).   Oxford  BioMedica has already  attracted  two
major pharmaceutical companies (Aventis and AstraZeneca) who
are  collaborating with the Company in its target validation
programme.

Summary financial information

Summary  financial information, extracted from  the  audited
financial  information for the years ended 31 December  1999
and 2000 is set out below:

                                         Year ended 31 December
                                                 1999      2000
                                                £'000     £'000
 Turnover                                         436       732
 Operating loss                                (4,407)   (5,936)
 Loss for the period                           (4,189)   (5,002)
 Loss per ordinary share                        (3.0p)    (3.1p)
 Net assets per ordinary share                   2.7p      7.5p


Current trading and prospects for Oxford BioMedica

Since  31 December 2000, trading has continued in line  with
expectations and Oxford BioMedica has announced a number  of
commercial  agreements, with Wyeth (19 January  2001)  under
which  Wyeth  gained  exclusive development  and  world-wide
marketing rights to an Oxford BioMedica anti-cancer  therapy
and  with the French Centre for National Scientific Research
and  the  University  of Montpelier (1 February  2001)  that
grants   Oxford  BioMedica  exclusive  access  to   antibody
technology   developed  by  Dr.  Marc  Piechaczyk   at   the
University  of  Montpelier.  Oxford BioMedica also  recently
announced  an  agreement with King's  College  London  under
which Oxford BioMedica gained exclusive use of a proprietary
gene,  RARb2, associated with nerve regeneration.  All these
agreements  are  regarded  by the  Company  as  having  been
entered into in the ordinary course of business.

The  agreement  with  Wyeth is the most significant  of  the
agreements  entered into by the Company  since  31  December
2000 and has the potential to generate up to $24 million  in
upfront and milestone payments prior to the commencement  of
royalty payments.  While the other agreements have potential
for  a  long  term  impact on the trading prospects  of  the
Company,  they  have had no material effect on  the  Company
since 31 December 2000.

The Directors estimate that the funding requirements for the
period   of   two  years  from  Admission  will  amount   to
approximately £28 million.  The Directors believe that  such
funding  requirements can be met from the Company's existing
cash resources and from the net proceeds of the Placing.  As
a  consequence  of  continuing investment  in  research  and
development, the Directors expect the Oxford BioMedica group
to continue making losses in 2001.

The  Company  intends  to spread the  risk  associated  with
product  development  by pursuing a strategy  that  aims  to
develop  a portfolio of products and commercial interactions
to  satisfy  a  broad  range of markets  for  its  products.
Oxford BioMedica is developing a number of key products  in-
house in the areas of cancer and neurodegenerative diseases,
while simultaneously placing the same technology and product
components alongside those of collaborative partners, who it
is  anticipated will pay for all, or a significant part,  of
the  research  and development programme,  to  generate  new
product opportunities.

This  strategy  is  supported  by  the  creation  of  Oxford
BioMedica's  Gene  Discovery  Division  in  August  2000  to
further  diversify the Company's revenue generation strategy
by  utilising  its proprietary technology to provide  target
validation   systems  and  target  identification   to   the
pharmaceutical industry.  Oxford BioMedica has two  products
in Phase I/II clinical trials, a further eight collaborative
arrangements for products in preclinical trials or  research
and  two  major  pharmaceutical  customers  for  its  target
validation programme.

Details of the Placing and the Open Offer

Oxford   BioMedica  proposes  to  raise  approximately   £27
million, net of fees and expenses, by way of a firm  Placing
of 54,550,000 new Ordinary Shares at 55p per share and up to
approximately  £10 million through an Open Offer  of  up  to
19,149,701 new Ordinary Shares at 55p per share.

Beeson Gregory has agreed, as agent for Oxford BioMedica, to
procure subscribers or, failing which, Rothschild and Beeson
Gregory  have  jointly agreed to subscribe as principals  at
the  Placing Price for the New Ordinary Shares which are  to
be issued in connection with the Placing.

Qualifying Shareholders are invited by Rothschild (as  agent
for the Company) to apply for as many Offer Shares (using  a
whole  number)  as they wish under the Open  Offer.  In  the
event that the Company receives valid applications under the
Open  Offer  for  more  than  19,149,701  Offer  Shares   in
aggregate, applications by Qualifying Shareholders  will  be
satisfied  in  full up to their pro rata basic  entitlement,
being:

   1 Offer Share      for every 9 Existing Ordinary Shares

held by them on the Record Date, and so in proportion to the
number  of  Existing Ordinary Shares then held.   Fractional
entitlements  to  Offer  Shares  will  not  be   issued   to
Qualifying Shareholders and no cash payment will be made  in
lieu   of   fractional   entitlements.    Accordingly,   the
entitlements of Qualifying Shareholders will be rounded down
to the nearest whole number of Offer Shares.  The Open Offer
is  not  being underwritten.  However, any Offer Shares  not
taken  up by Qualifying Shareholders may be placed by Beeson
Gregory, as agent for the Company and for the benefit of the
Company,  at  a  price per Ordinary Share no less  than  the
Placing Price.

Applications  in excess of a Qualifying Shareholder's  basic
entitlement  will  be  satisfied only  to  the  extent  that
applications by other Qualifying Shareholders are  made  for
less  than  their guaranteed minimum pro rata  entitlements.
Allocations   of   Offer  Shares  in   respect   of   excess
applications will be made pro rata to the number  of  excess
shares applied for.

Qualifying Shareholders should be aware that the Open  Offer
is  not a rights issue and that Offer Shares not applied for
under the Open Offer will not be sold in the market for  the
benefit of Qualifying Shareholders who do not apply for them
under  the  Open Offer.  Application forms are  personal  to
shareholders  and may not be transferred except  to  satisfy
bona fide market claims.

The  Placing  and  the Open Offer are both conditional  upon
approval  by  Shareholders and Admission by  no  later  than
Tuesday,  17 April 2001, or such later date (being no  later
than Tuesday, 1 May 2001) as Rothschild may decide.

Use of Proceeds

The  net proceeds of the Placing and the Open Offer will  be
used  to  continue to strengthen the Company and to progress
the  candidate products to a stage where they  can  generate
significant revenues for the Group.  The Directors intend to:

*     develop  the Company's product pipeline by  increasing
      the Company's clinical trial programme;
*     increase  the resources that are applied  to  building
      alliances with major pharmaceutical companies;
*     further strengthen the Company's intellectual property
      position  from   both  in-house   activities  and  in-
      licensing; and
*     establish  a  US  operation for business  development,
      clinical trials and new product development.

The  Directors estimate that the net proceeds of the Placing
are expected to be £27 million, of which £12 million will be
invested in further research and development in gene therapy
and gene-based immunotherapy, £6 million will be invested in
preclinical  and  early  clinical development  of  candidate
products,   and   £9  million  will  be  invested   in   the
establishment of operations in the United States of America.
Included  in  these estimates is capital expenditure  of  £5
million.   It is the Directors' current intention  to  place
the funds on deposit pending use.

The  Directors' current intention is to apply  any  proceeds
received  pursuant  to  the  Open  Offer  to  increase   the
investment  made by the Company in the areas  identified  in
the paragraph above.

As a result of the institutional cash placing in August 2000
which  raised  net  proceeds of  £8.5  million,  the  Oxford
BioMedica Group had cash balances totalling £11.6 million at
31 December 2000.  The Directors intend that the majority of
this will be used to fund the Gene Discovery Division.

Lock-up Agreements

All of the Directors, their spouses and senior employees  of
Oxford  BioMedica who will hold Ordinary Shares  or  options
over  Ordinary Shares at Admission have agreed not  to  sell
Ordinary  Shares  during  the  six  month  period  following
Admission.  However, this lock-up does not apply in  respect
of  909,091 Ordinary Shares held by Susan Kingsman,  363,516
Ordinary Shares held by Andrew Wood and/or over which Andrew
Wood  has options, 48,808 Ordinary Shares over which  Sharon
Wood  has  options, 440,000 Ordinary Shares  held  by  Neill
MacKenzie and/or over which Neill MacKenzie has options  and
60,000  Ordinary Shares held by Julia MacKenzie,  and  those
persons  are  free  to sell such shares at  any  time  after
Admission.   In addition, the lock-up does not  apply  to  a
sale of Ordinary Shares on exercise by Prelude Trust plc  of
an  option granted to it by Alan Kingsman and Susan Kingsman
to  acquire up to 938,549 and 952,861 of the Ordinary Shares
held by them, respectively.

Prelude  Trust plc, a major shareholder in Oxford BioMedica,
The  Chancellor, Masters and Scholars of the  University  of
Oxford  and ATM Investments Limited have agreed not to  sell
Ordinary  Shares  held  by  them  (or  to  which  they   are
beneficially  entitled) at Admission, during the  six  month
period following Admission.  However, this lock-up does  not
apply  in  respect  of 4,545,454 Ordinary  Shares  held  (or
beneficially  owned)  by  Prelude Trust  plc  and  2,624,272
Ordinary  Shares held by ATM Investments Limited  and  those
shareholders are free to sell such shares at any time  after
Admission.   In addition, the lock-up does not  apply  to  a
sale of Ordinary Shares on exercise by Prelude Trust plc  of
an  option  granted  to  it by ATM  Investments  Limited  to
acquire  up  to 570,552 of the Ordinary Shares held  by  ATM
Investments Limited.

Recommendation

The  Directors of Oxford BioMedica, who have been so advised
by Rothschild, the Company's financial adviser, consider the
Admission, the Placing and the Open Offer to be in the  best
interests  of the Company and its shareholders as  a  whole.
In  providing advice to the Directors, Rothschild has  taken
into account the Directors' commercial assessments.

The  Directors  of  Oxford BioMedica  unanimously  recommend
Shareholders to vote in favour of all the Resolutions to  be
proposed  at  the  Extraordinary General Meeting  and  those
Directors holding Ordinary Shares have undertaken to vote in
favour  of the Resolutions in respect of their own aggregate
beneficial   holdings   of   18,972,800   Ordinary   Shares,
representing  11.01  per  cent. of  the  Company's  Existing
Ordinary  Shares.   In  addition, Prelude  Trust  plc,  Alan
Goodman, ATM Investments Limited and The Chancellor, Masters
and Scholars of the University of Oxford have undertaken  to
vote  in  favour of the Resolutions in respect of their  own
aggregate beneficial holdings of 33,381,667 Ordinary Shares,
representing  19.37  per  cent.  of  the  Existing  Ordinary
Shares.

Timetable

Record date for the Open Offer             Friday, 2 March 2001

Latest time and date for splitting       3.00 p.m., Thursday, 5
Application Forms                                    April 2001
(to satisfy bona fide market claims)

Latest time and date for receipt of        3.00 p.m., Monday, 9
completed Application Forms and                      April 2001
payment in full under the Open Offer

Latest time and date for receipt of      4.00 p.m., Tuesday, 10
forms of proxy                                       April 2001

Time and date of Extraordinary General  4.00 p.m., Thursday, 12
Meeting                                              April 2001

Admission and commencement of dealings   Tuesday, 17 April 2001
in the Existing Ordinary Shares and 
New Ordinary Shares

CREST accounts credited                 Thursday, 19 April 2001
                                                               
Despatch of share certificates          Thursday, 26 April 2001
                                                               

For further information:

Oxford BioMedica plc                         [phone]
Alan Kingsman, Chief Executive

N M Rothschild & Sons Limited               [phone]
Tony Stuart

Beeson Gregory Limited                      [phone]
Nick Rodgers

Merlin Financial                            [phone]
David Simonson
Melanie Toyne Sewell

HCC De Facto Group                          [phone]
Chris Gardner


Rothschild, which is regulated by The Securities and Futures
Authority  Limited,  is  acting  as  financial  adviser  and
sponsor  to  Oxford  BioMedica plc in  connection  with  the
Admission,  the Placing and the Open Offer and no  one  else
and  will not be responsible to any person other than Oxford
BioMedica plc, for providing the protections afforded to its
customers  or  for  providing  advice  in  relation  to  the
Admission, the Placing and the Open Offer.

Beeson  Gregory,  which is regulated by the  Securities  and
Futures  Authority Limited, is acting as  broker  to  Oxford
BioMedica plc in connection with the Admission, the  Placing
and  the  Open  Offer  and  no one  else  and  will  not  be
responsible  to any person other than Oxford BioMedica  plc,
as  broker,  for providing the protections afforded  to  its
customers  or  for  providing  advice  in  relation  to  the
Admission, the Placing and the Open Offer.

The Open Offer is not being made, directly or indirectly, in
or  into,  or  by  use  of the mails, or  by  any  means  or
instrumentality  (including, without  limitation,  facsimile
transmission, telex or telephone) of interstate  or  foreign
commerce,   or  any  facilities  of  a  national  securities
exchange  of  the  United States or  Canada  and  cannot  be
accepted by any such use, means, instrumentality or facility
in  or  from within the United States or Canada and  is  not
being made directly or indirectly in or into the Republic of
Ireland, Australia or Japan.

This document is not an offer of securities for sale in  the
United States and the New Ordinary Shares have not been, and
will  not  be, registered under the United States Securities
Act of 1933 (as amended), nor under the laws of any state of
the  United States, and the relevant clearances have not and
will  not  be  obtained  from the  relevant  authorities  in
Canada,  the  Republic  of  Ireland,  Australia  or   Japan.
Accordingly, New Ordinary Shares may not be offered, sold or
delivered   directly,  or  indirectly  in   or   into   such
jurisdictions.

This  document  contains a summary of information  extracted
from the Prospectus dated 12 March 2001, copies of which are
available for inspection at the Document Viewing Facility of
the  Financial  Services Authority, 25 The North  Colonnade,
London  E14 5HS during normal business hours on any  weekday
(excluding  Saturday, Sunday and public holidays)  from  the
date  of  this  announcement up to and including  Monday,  9
April 2001.
                         APPENDIX 1

                         Definitions

The  following  definitions apply throughout  this  document
unless the context otherwise requires:

'Admission'         admission   to   (i)  the  Official   List
                    becoming effective and (ii) trading by the
                    London  Stock  Exchange  of  the  Existing
                    Ordinary  Shares, the Placing  Shares  and
                    such of the Offer Shares as are issued  on
                    completion  of the Placing  and  the  Open
                    Offer
'AIM'               Alternative Investment Market
'Application Form'  the   application  form  accompanying  the
                    Prospectus  and being sent  to  Qualifying
                    Shareholders in connection with  the  Open
                    Offer
'Aventis'           Aventis Pharmaceuticals Inc.
'Beeson Gregory'    Beeson Gregory Limited
'CREST'             the  computerised  settlement  system   to
                    facilitate the transfer of title to shares
                    in   uncertificated  form,   operated   by
                    CRESTCo Limited
'Directors' or      the directors of the Company from time  to
'Board'             time
'Existing Ordinary  the  172,347,312 Ordinary  Shares  of  the
Shares'             Company  in  issue as at Friday,  9  March
                    2001  (being  the latest practicable  date
                    prior to the posting of the Prospectus)
'Extraordinary      the   extraordinary  general  meeting   of
General Meeting'    Oxford  BioMedica proposed to be  held  on
or 'EGM'            Thursday, 12 April 2001, at which, amongst
                    other things, the resolutions necessary to
                    enable  the Placing and the Open Offer  to
                    proceed  will be proposed, as set  out  in
                    the  notice  at the end of the Prospectus,
                    and any adjustment thereof
'IDM'               IDM S.A.
'London Stock       London Stock Exchange plc
Exchange'
'New Ordinary       the Placing Shares and the Offer Shares
Shares'
'Nycomed Amersham'  Nycomed Amersham plc
'Offer Shares'      up to 19,149,701 new Ordinary Shares to be
                    issued  for  cash  at  the  Placing  Price
                    pursuant to the Open Offer
'Official List'     Official List of the UK Listing Authority

'Open Offer'        the invitation by Rothschild on behalf  of
                    the Company to Qualifying Shareholders  to
                    apply to subscribe for Offer Shares on the
                    terms  and  subject to the conditions  set
                    out   in   the  Prospectus  and   in   the
                    Application Form
'Ordinary Shares'   ordinary  shares of 1p each in  the  share
                    capital of the Company
'Oxford BioMedica   Oxford BioMedica and its subsidiaries
Group' or 'Group'
'Oxford BioMedica'  Oxford BioMedica plc
or 'the Company'
'Placees'           certain  institutional and other investors
                    who  have  agreed  to  subscribe  for  new
                    Ordinary Shares pursuant to the Placing
'Placing'           the  conditional placing  of  the  Placing
                    Shares by Beeson Gregory as agent for  the
                    Company  at the Placing Price pursuant  to
                    the Placing Agreement
'Placing Price'     55p per new Ordinary Share
'Placing Shares'    the  54,550,000 New Ordinary Shares to  be
                    issued  for cash at the Placing  Price  to
                    the Placees
'PolyMASC'          PolyMASC   Limited,   a   subsidiary    of
                    Valentis, Inc.
'Qualifying         Shareholders  on  the register  of  Oxford
Shareholders'       BioMedica  at  the  Record  Date  who  are
                    entitled  to take part in the  Open  Offer
                    excluding certain overseas shareholders as
                    set out in the Prospectus
'Record Date'       the  record date for the Open Offer, being
                    the  close of business on Friday  2  March
                    2001
'Resolutions'       the  resolutions  to be  proposed  at  the
                    Extraordinary General Meeting
'Rothschild'        N M Rothschild & Sons Limited
'Shareholders'      holders of Existing Ordinary Shares
'US', 'USA' or      the   United   States  of   America,   its
'United States of   territories and possessions, any state  of
America'            the  United  States  of  America  and  the
                    District of Columbia
'Virbac'            Virbac S.A.
'Wyeth'             Wyeth-Ayerst  Laboratories   Division,   a
                    division of American Home Products, Inc.